NYSE:LLYPharmaceuticals
How Investors Are Reacting To Eli Lilly (LLY) FDA Approval of New Kisunla Dosing Schedule
Earlier this month, Eli Lilly received U.S. FDA approval for an updated dosing schedule of Kisunla (donanemab-azbt), its amyloid-targeting therapy for adults with early symptomatic Alzheimer's disease, which was shown to significantly reduce the risk of imaging abnormalities associated with treatment.
This label change, based on recent clinical trial data, highlights efforts to enhance the safety profile of Kisunla while maintaining its efficacy, potentially supporting broader patient...